Skip to Main Content

Advertisement

Skip Nav Destination

Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

Mol Cancer Ther (2015) 14 (12_Supplement_2): PR14.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Maaz Tahir Sadiq
  • Juliette Servante
  • Srinivasan Madhusudan
Expert Review of Precision Medicine and Drug Development (2021) 6 (4): 259.
  • Francis M. Barnieh
  • Paul M. Loadman
  • Robert A. Falconer
Current Research in Pharmacology and Drug Discovery (2021) 2: 100017.
  • Charles R. Dunlop
  • Yann Wallez
  • Timothy Isaac Johnson
  • Sandra Bernaldo de Quirós Fernández
  • Stephen T. Durant
  • Elaine B. Cadogan
  • Alan Lau
  • Frances M. Richards
  • Duncan I. Jodrell
British Journal of Cancer (2020) 123 (9): 1424.
  • M.W. Wong-Brown
  • A. van der Westhuizen
  • N.A. Bowden
Clinical Oncology (2020) 32 (8): 518.
  • Samuel H. Myers
  • Jose Antonio Ortega
  • Andrea Cavalli
Journal of Medicinal Chemistry (2020) 63 (23): 14151.
  • Daisy W.S. Mak
  • Su Li
  • Anna Minchom
European Journal of Cancer (2019) 119: 132.
  • Lin Mei
  • Junran Zhang
  • Kai He
  • Jingsong Zhang
Journal of Hematology & Oncology (2019) 12 (1)
  • Laura Carrassa
  • Giovanna Damia
Cancer Treatment Reviews (2017) 60: 139.
  • Raghav Sundar
  • Jessica Brown
  • Alvaro Ingles Russo
  • Timothy A. Yap
Current Problems in Cancer (2017) 41 (4): 302.
  • Aimee Bence Lin
  • Samuel C. McNeely
  • Richard P. Beckmann
Clinical Cancer Research (2017) 23 (13): 3232.
  • Jessica S. Brown
  • Brent O'Carrigan
  • Stephen P. Jackson
  • Timothy A. Yap
Cancer Discovery (2017) 7 (1): 20.
Close Modal

or Create an Account

Close Modal
Close Modal